trametinib,dabrafenib
novartis
 dabrafenib plus trametinib in patients with braf v600e-mutant anaplastic thyroid cancer: updated analysis from the roar basket study confirms the definitive benefit of braf+mek in atc with long-term follow-up 
Oncologist | Associate Prof | Executive Director-Research, MD Anderson Cancer Network | Medical Director, Clinical Center for Targeted Therapy. Tweets = my own.